Improvement of level MDA and SOD Using of Ganoderma Lucidum as Adjunctive Treatment for Statin Based Therapy in High Risk Patient Based on Framingham Score

Abstract

It is well known from previous research on the importance of antioxidants to inhibit the progression of coronary heart disease in high-risk patients based on framingham scores. Statins are routinely administered in high-risk patients  based on the Dyslipidemia 2016 ESC guidelines but the effects of adding Ganoderma are known to have antioxidant effects, in patients who have received statins. This study aims to assess the effect of antioxidants through measurement of SOD and MDA in patients given a combination of Ganoderma lucidum with statins.Method: A total of 24 patients with high-risk patients based on the Framingham score > 20% were selected as sample of study. Patients with respondents who had never received statin therapy or ACEi or ARB or CCB or beta blocker, or did not routinely consume the drug for 2 weeks were excluded from this study. The addition of Ganoderma lucidum dose of 3x250 mg was added to statins as the first group and Ganoderma lucidum dose of 3x250 mg was added to the Statin combination of Angiotensin Converting Enzym inhibitors (ACE inhibitors) or Angiotensin Receptor Blockers (ARB) and or Calcium Channel Blockers (CCB) and or Beta blockers as second group for 90 days. SOD and MDA levels were measured before and after the administration of Ganoderma Lucidum with the ELISA method.Result: After the administration of Ganoderma Lucidum with standard therapy, there was a decrease in MDA levels and an increase in SOD levels after 90 days in two groups. Conclusion: The addition of Ganoderma Lucidum to standard therapy can reduce oxidant levels in high-risk patients based on framingham scores.

Keyword: Superoxyde-dismutase, Malondyaldehide, Oxidative Stress, Antioxidant, Ganoderma Lucidum, Statin

Downloads

Download data is not yet available.

References

Institute of Medicine Committee on Preventing the
Global Epidemic of Cardiovascular Disease: Meeting
the Challenges in Developing C. The National
Academies Collection: Reports funded by National
Institutes of Health. In: Fuster V, Kelly BB, editors.
Promoting Cardiovascular Health in the Developing
World: A Critical Challenge to Achieve Global
Health. Washington (DC): National Academies
Press (US) National Academy of Sciences.; 2010.
2. Delima LM, Hadi Siswoyo. Prevalensi dan faktor
determinan penyakit jantung di Indonesia Bul Penelit
Kesehat. 2009;37:: 142 - 15.
3. Gui T, Shimokado A, Sun Y, Akasaka T, Muragaki
Y. Diverse roles of macrophages in atherosclerosis:
from inflammatory biology to biomarker discovery.
Mediators of inflammation. 2012;2012:693083
4. Chen SN, Nan FH, Chen S, Wu JF, Lu CL, Soni
MG. Safety assessment of mushroom beta-glucan:
subchronic toxicity in rodents and mutagenicity
studies. Food and chemical toxicology : an international
journal published for the British Industrial Biological
Research Association. 2011;49(11):2890-8.
5. Wang XC, Xi RJ, Li Y, Wang DM, Yao YJ. The
species identity of the widely cultivated Ganoderma,
'G. lucidum' (Ling-zhi), in China. PloS one.
2012;7(7):e40857
6. Shirley R, Ord ENJ, Work LM. Oxidative Stress
and the Use of Antioxidants in Stroke. Antioxidants.
2014;3(3):472-501.
7. Pashkow FJ. Oxidative Stress and Inflammation
in Heart Disease: Do Antioxidants Have a Role in
Treatment and/or Prevention? International journal
of inflammation. 2011;2011:514623.
8. Smina TP, Mathew J, Janardhanan KK, Devasagayam
TP. Antioxidant activity and toxicity profile of
total triterpenes isolated from Ganoderma lucidum
(Fr.) P. Karst occurring in South India. Environmental
toxicology and pharmacology. 2011;32(3):438-
46.
9. Smina TP, Mathew J, Janardhanan KK, Devasagayam
TP. Antioxidant activity and toxicity profile of
total triterpenes isolated from Ganoderma lucidum
(Fr.) P. Karst occurring in South India. Environmental
toxicology and pharmacology. 2011;32(3):438-
46.
10. Pan D, Zhang D, Wu J, Chen C, Xu Z, Yang H, et
al. Antidiabetic, antihyperlipidemic and antioxidant
activities of a novel proteoglycan from ganoderma
lucidum fruiting bodies on db/db mice and the possible
mechanism. PloS one. 2013;8(7):e68332.
11. Lee J LP. Lipoproteins and the Endothelium: Past,
Present and Future Hellenic journal of cardiology
: HJC = Hellenike kardiologike epitheorese.
206;47:158-9.
12. Casieri V, Matteucci M, Cavallini, et.al. Long term
intake of pasta containing barley (1-3) beta-D-glucan
increases neovascularization-mediated cardioprotection
through endothelial upregulation of
vascular endothelial growth factor and parkin. Scientific
Reports, 2017:13424
13. Taylor F, Huffman MD, Macedo AF, et al. Statins
for the primary prevention of cardiovascular disease.
Cochrane Database Syst Rev 2013; (1): CD004816.
14. Mihaylova B, Emberson J, Blackwell L, et al. The
effects of lowering LDL cholesterol with statin therapy
in people at low risk of vascular disease: meta-
analysis of individual data from 27 randomised
trials. Lancet 2012; 380(9841): 581–590.
15. Taylor F, Huffman MD, Macedo A, Moore THM,
Burke M, Davey Smith G, Ward K, Ebrahim S.
Statins for the primary prevention of cardiovascular
disease. 31 January 2013
16. Wilck N and Ludwig A. Targeting the ubiquitin-
proteasome system in atherosclerosis: Status
quo, Challenges and perspectives. Antioxidants &
redox signaling volume 21,number 17,2014
17. Alexios S. Antonopoulos, Marios Margaritis, Regent
Lee, Keith Channon, and Charalambos Antoniades.
Statins as Anti-Inflammatory Agents in Atherogenesis:
Molecular Mechanisms and Lessons from the
Recent Clinical Trials. Current Pharmaceutical Design,
2012, 18, 1519-153
18. Wilck N and Ludwig A. Targeting the ubiquitin-
proteasome system in atherosclerosis: Status
quo, Challenges and perspectives. Antioxidants &
redox signaling volume 21,number 17,2014
19. Alexios S. Antonopoulos, Marios Margaritis, Regent
Lee, Keith Channon, and Charalambos Antoniades.
Statins as Anti-Inflammatory Agents in Atherogenesis:
Molecular Mechanisms and Lessons from the
Recent Clinical Trials. Current Pharmaceutical Design,
2012, 18, 1519-153
20. Vasankari T, Ahotupa M, Viikari J, Nuotio I,
Strandberg T, Vanhanen H, Gylling H, Miettinen
T, Tikkanen MJ. Effect of 12-month statin therapy
on antioxidant potential of LDL and serum antioxidant
vitamin concentrations. Ann Med 2004;36:
618–622.
Published
2019-09-11
How to Cite
Improvement of level MDA and SOD Using of Ganoderma Lucidum as Adjunctive Treatment for Statin Based Therapy in High Risk Patient Based on Framingham Score. (2019). Indonesian Journal of Cardiology, 39(3). https://doi.org/10.30701/ijc.v39i3.820